Target intelligence / Profile preview

Platelet activation signaling pathway

Molecular classification
G-protein-coupled receptors (GPCRs), Integrins (particularly glycoprotein IIb/IIIa or αIIbβ3), Glycoprotein receptors (GPVI, GPIb-IX), Phospholipase C (PLC) families: PLCβ, PLCγ, and PLCδ, Phospholipase D (PLD) isoforms: PLD1 and PLD2, Phosphoinositide 3-kinase (PI3K), Protein kinase C (PKC), Akt isoforms (Akt1, Akt2, Akt3), G-Protein Subfamilies: Gq/G11, G12/G13, Gi/Go/Gz, Gs
01

Overview

The platelet activation pathway is a complex network of signaling events triggered by various agonists including thrombin, ADP, thromboxane A2, collagen, and von Willebrand factor. These agonists bind to specific receptors on platelets, initiating intracellular signaling cascades that converge on common effectors like phospholipase C, leading to calcium mobilization, granule secretion, and integrin activation. This ultimately results in platelet shape change, adhesion, aggregation, and thrombus formation. The pathway involves multiple receptor families, G-proteins, kinases, and second messengers, making it a sophisticated system with built-in amplification and synergy between different activation mechanisms. Due to its central role in thrombosis, the platelet activation pathway contains numerous therapeutic targets for the prevention and treatment of cardiovascular diseases.

Other names
Platelet activation cascadePlatelet signaling pathwayPlatelet-dependent thrombosis pathway
02

Mechanism of action

P2Y12 inhibitors block ADP-mediated platelet activation and aggregation. Glycoprotein IIb/IIIa inhibitors prevent fibrinogen binding and platelet aggregation.

03

Biological functions

G-Protein-Coupled Receptor SignalingPhospholipase C ActivationCalcium Mobilization and Granule SecretionIntegrin Activation (inside-out and outside-in signaling)
04

Disease associations

Thrombosis and hemostasisCardiovascular diseasesInflammatory responsesWound healing
05

Safety considerations

High on-treatment platelet reactivity with P2Y12 inhibitorsChallenges related to the short half-life of clopidogrel and prasugrelContribution of platelet turnover to treatment resistance
06

Interacting drugs

P2Y12 receptor inhibitors (thienopyridines like clopidogrel and prasugrel)

1 more in the full profile.

Beyond the preview

Go deeper on Platelet activation signaling pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Platelet activation signaling pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call